NEW YORK (GenomeWeb News) — Illumina has increased by $25 million a convertible note offering it disclosed yesterday, making the total sale worth $350 million, the company said today.
 
The company said it plans to use the proceeds to pay for corporate expenses, and will use around $202 million of it to buy back its own stock or cover acquisition costs.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.